Previous 10 | Next 10 |
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference PR Newswire If successful, REC-2282 could be the first approved treatment for NF2 -mutated meningiomas, which are debilitatin...
2022 has been brutal for early-stage biotech companies. Cathie Wood's Ark Genomic Revolution ETF is down 60% over the past year. Wood's long-term performance is outstanding, however, even after that huge drop. Some of her stocks have gotten a lot cheaper in the short term. But the poten...
Recursion Pharmaceuticals press release (NASDAQ:RXRX): Q1 GAAP EPS of -$0.33 misses by $0.84. Revenue of $5.4M (+107.7% Y/Y) misses by $78.55M. For further details see: Recursion Pharmaceuticals GAAP EPS of -$0.33 misses by $0.84, revenue of $5.4M misses by $78.55M
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results PR Newswire Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical...
Recursion to Participate in Upcoming Investor Conference PR Newswire SALT LAKE CITY , May 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announce...
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis PR Newswire SALT LAKE CITY , April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company i...
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital PR Newswire The total capital represents the largest seed financing for life science startups in Utah's history SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- Alt...
Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...